ArticleAvian diseases2026
History of Avian Metapneumovirus Subtype C in the United States.
Article in Avian diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Avian Metapneumovirus: Virology, Epidemiology, and Insights from a Comparative Analysis with Human Metapneumovirus-A Review.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Since its first detection in turkeys in South Africa in the late 1970s, avian metapneumovirus (aMPV) has emerged as a major pathogen of concern for poultry worldwide, causing acute respiratory disease with significant economic consequences. The virus has spread throughout every continent besides Australia, with distinct subtypes (A-D) identified in different regions and hosts. In the United States, the emergence of subtype C in the mid-1990s led to widespread outbreaks in turkeys and established an endemic presence for almost a decade. Eradication efforts took years of surveillance, molecular characterization of the new subtype, concentrated region-wide eradication plans, and vaccine development before they were fully successful. The recent detection of new subtypes (subtypes A and B) in the United States in 2024, after nearly two decades of aMPV-free status, underscores the continual need for vigilant monitoring and adaptive management of this highly contagious and impactful respiratory disease. This review seeks to cover the historical emergence, progression, and eradication of aMPV subtype C (aMPV/C) in the United States, while drawing on lessons learned from the epidemic for the broader global avian industry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.